Publication: Long non-coding RNA C20orf56 as a predictor of response to neoadjuvant CCRT and survival rates of rectal cancers
Authors
Cheng-Fa Yeh ; Ching-Chieh Yang ; Yi-Kai Kao ; Pin-Chun Chen ; Po-Wen Yang ; Sung-Wei Lee ; Yu-Feng Tian ; Yu-Hsuan Kuo ; Li-Ching Wu ; Chien-Feng Li ; Yi-Che Chang Chien ; I-Wei Chang ; Chih-I Chen
item.page.secondaryauthor
item.page.director
Publisher
publication.page.editor
Universidad de Murcia, Departamento de Biología Celular e Histología
publication.page.department
DOI
https://doi.org/10.14670/HH-18-979
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Introduction. Colorectal cancer is the third
most prevalent malignancy and the second leading cause
of cancer mortality worldwide. Neoadjuvant concurrent
chemoradiotherapy (CCRT) improves survival and
increases curative surgery rates in rectal cancer.
C20orf56, a long non-coding RNA (lncRNA), plays
diverse roles in cancer, but its association with
neoadjuvant CCRT response and prognosis in rectal
cancer remains unexplored.
Materials and Methods. Tumor samples from 343
rectal cancer patients who received neoadjuvant CCRT
followed by surgery were analyzed for C20orf56
expression via in situ hybridization. Associations
between C20orf56 expression and clinicopathological
parameters were evaluated with the χ² test. Survival
outcomes were assessed using the Kaplan-Meier method and compared by log-rank tests, while multivariate
analysis was conducted using a Cox proportional
hazards model. Additionally, an independent cohort of
responders and non-responders (n=8 per group) was
used to validate C20orf56 transcript levels by real-time
RT-PCR.
Results. A transcriptomic analysis (GSE35452)
identified C20orf56 as differentially expressed between
responders and non-responders. Decreased expression of
C20orf56 showed significant correlations with less
advanced post-treatment tumor invasiveness, negative
post-treatment nodal metastasis, absence of vascular
invasion and perineural invasion, and improved response
to neoadjuvant CCRT (all p≤0.024). Diminished
expression of C20orf56 was associated not only with
favorable disease-specific survival (DSS), local
recurrence-free survival (LRFS), and metastasis-free
survival (MeFS) (all p<0.0001) in univariate analysis but
also functioned as an independent predictor signifying
enhanced clinical outcomes, including DSS, LRFS, and
MeFS (all p<0.001). In the real-time RT-PCR analysis,
the transcriptomic levels were significantly lower in the responder group compared with the non-responder group
(p=0.007).
Conclusion. C20orf56 may play a significant role in
rectal cancer progression and response to neoadjuvant
CCRT, serving as a novel prognostic factor.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by-nc-nd/4.0/